Glenmark Pharmaceuticals has been granted a patent for hetero-dimeric immunoglobulins that bind to CD3 and a disease-associated antigen. These engineered immunoglobulins can be purified to a high degree using a Protein A differential purification technique. GlobalData’s report on Glenmark Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Glenmark Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Glenmark Pharmaceuticals's grant share as of February 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Hetero-dimeric immunoglobulins for binding cd3 and disease antigens
A recently granted patent (Publication Number: US11891454B2) discloses a hetero-dimeric immunoglobulin or its fragment, consisting of two polypeptides - one binding to Protein A and CD3 protein complex, and the other binding to CD38. The second polypeptide has a modified VH3 domain with reduced binding to Protein A. The engineered immunoglobulin constant region of both polypeptides contains specific amino acid substitutions at the protein-protein interface. Additionally, the patent details various amino acid sequences and substitutions in the epitope binding regions of the polypeptides, highlighting their specificity towards CD3 protein complex and CD38.
Furthermore, the patent includes methods for producing the hetero-dimeric immunoglobulin in vitro, involving steps like preparing DNA vectors encoding the polypeptides, transfecting them into mammalian host cells, culturing, and purifying the immunoglobulin using Protein A affinity chromatography. The method ensures the purity of the final product, with the purified material being at least 95% pure as determined by capillary electrophoresis. Overall, the patent provides a detailed insight into the structure, composition, and production of a novel hetero-dimeric immunoglobulin with specific binding capabilities, potentially opening avenues for therapeutic applications targeting CD3 protein complex and CD38.
To know more about GlobalData’s detailed insights on Glenmark Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
